Results 41 to 50 of about 21,917 (243)
Mutations strengthened SARS-CoV-2 infectivity [PDF]
arXiv, 2020 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is a major concern in coronavirus disease 2019 (COVID-19) prevention and economic reopening. However, rigorous determination of SARS-COV-2 infectivity is essentially impossible owing to its continuous evolution with over 13752 single nucleotide polymorphisms (SNP) variants in six ...
arxiv
Clinical dichotomania: A major cause of over-diagnosis and over-treatment? [PDF]
arXiv, 2023 Introduction: There have been many warnings that inappropriate dichotomisation of results into positive or negative, high, or normal etc., during medical research could be very damaging. The aim of this paper is to argue that this is the main cause of over-diagnosis and over-treatment.
arxiv
Decoding Blastocystis‐Driven Mechanisms in Gut Microbiota and Host Metabolism
Advanced Science, EarlyView.Blastocystis, a prevalent gut microbe, interacts with the host through metabolic and immune pathways, influencing cardiometabolic health. This perspective explores its role in modulating short‐chain fatty acid production, tryptophan metabolism, and immune signaling, potentially impacting cholesterol absorption, glucose metabolism, and vascular health ...
Lei Deng, Kevin SW Tan
wiley +1 more source
Clinical Cardiology, Volume 45, Issue 12, Page 1236-1245, December 2022., 2022 Long‐term survival stratified for weight classes illustrated by Hazard plot for patients treated with MitraClip® implantation stratified for weight classes. Association of weight class compared to normal‐weight with long‐term survival (adjusted for Logistic EuroScore).
Karsten Keller +12 more
wiley +1 more source
Modelling and docking of Indian SARS-CoV-2 spike protein 1 with ACE2: implications for co-morbidity and therapeutic intervention [PDF]
arXiv, 2020 Presently, India bears amongst the highest burden of non-communicable diseases such as diabetes mellitus (DM), hypertension (HT), and cardio vascular disease (CVD) and thus represents a vulnerable target to the SARS-CoV-2/COVID-19 pandemic. Involvement of the angiotensin converting enzyme 2 (ACE2) in susceptibility to infection and pathogenesis by SARS-
arxiv
Advanced Science, EarlyView.Canopy FGF signaling regulator 2 (CNPY2) which is contributed to ERS is upregulated in the renal tubules of patients with diabetic nephropathy (DN). Mechanistically, CNPY2 may regulate ferroptosis and MAM integrity in renal tubular epithelial cells through PERK/ATF4/CHAC1 pathway, thereby promoting the progression of DN.
Jingfang Chen +9 more
wiley +1 more source
Clinical Cardiology, Volume 45, Issue 12, Page 1220-1228, December 2022., 2022 Abstract Background Cardiovascular medications are vital for the secondary prevention of coronary arterial disease (CAD). However, the effect of cardiovascular medication may depend on the optimal adherence of the patients. This meta‐analysis aims to determine the magnitude of adherence to vascular medications that influences the absolute and relative ...
Chen Chen +5 more
wiley +1 more source
A computational insight of the improved nicotine binding with ACE2-SARS-CoV-2 complex with its clinical impact [PDF]
arXiv, 2020 Smokers being witnessed with the mild adverse clinical symptoms of SARS-CoV-2, the in-silico study is intended to explore the effect of nicotine binding to the soluble angiotensin converting enzyme II (ACE2) receptor with or without SARS-CoV-2 binding.
arxiv
Angiotensin Receptors and Aging [PDF]
Hypertension, 2007 The major biological actions of the renin–angiotensin system are mediated by angiotensin (Ang) II, which binds with equal affinity to Ang type 1 (AT1) and type 2 (AT2) receptors. The majority of Ang II actions, however, are mediated by the AT1 receptor, including vasoconstriction, cellular proliferation, tissue growth, direct renal tubular sodium ...
openaire +2 more sources
Angiotensin Ii Receptor Blockers [PDF]
Baylor University Medical Center Proceedings, 2003 The ARBs have very similar clinical profiles. They do, however, have different pharmacokinetic profiles, which may lead to some differences in efficacy. The newer agents irbesartan, candesartan, telmisartan, and olmesartan have longer half-lives and durations of action than the older agents losartan and valsartan (5).
Cheryle Gurk-Turner, Amy Barreras
openaire +3 more sources